NutriBand (NTRB) Capital Leases (2020 - 2023)

NutriBand (NTRB) posted Capital Leases of $34277.0 for Q1 2023, down 19.1% sequentially from $42369.0 in Q4 2022.

NutriBand (NTRB) Capital Leases (2020 - 2023) Analysis & Trends

NutriBand has reported Capital Leases for 4 years, with the latest figure at $34277.0 in Q1 2023.

Quarterly Capital Leases changed N/A year-over-year to $34277.0 in Q1 2023, while the trailing twelve-month figure through Jan 2023 was $34277.0 (changed N/A YoY) and the FY2023 annual result came in at $34277.0, changed N/A from the prior year.
Capital Leases retreated to $34277.0 in Q1 2023 per NTRB's latest filing, from $42369.0 in the prior quarter.
Over five years, Capital Leases peaked at $103688.0 in Q4 2020 and troughed at $34277.0 in Q1 2023.
A 4-year average of $72814.0 and a median of $74712.5 in 2021 frame the typical range for Capital Leases.
The widest YoY moves for Capital Leases: up 21.81% in 2022, down 27.45% in 2022.
Over 4 years, Capital Leases stood at $103688.0 in 2020, then fell by 19.13% to $83856.0 in 2021, then tumbled by 49.47% to $42369.0 in 2022, then declined by 19.1% to $34277.0 in 2023.
According to Business Quant data, Capital Leases over the past three periods registered $34277.0, $42369.0, and $65569.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	NutriBand	57.74 Mn	53.73 Mn	196,801.00

Download Data